drugset
drugset / Trial / NCT03706911

Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects

NCT03706911 ↗

Phase 1 Completed 27 enrolled Viriom
RandomizedSequentialOpen-labelTreatment

Summary

To evaluate safety and tolerability of VM-1500A-LAI after its single and multiple intramuscular ascending dose to healthy volunteers

Timeline

Start
2019-01-21
Primary completion
2020-03-27
Completion
2020-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject DEPULFAVIRINE Small molecule 150 mg Intramuscular
Subject DEPULFAVIRINE Small molecule 300 mg Intramuscular
Subject DEPULFAVIRINE Small molecule 600 mg Intramuscular
Subject DEPULFAVIRINE Small molecule 1200 mg Intramuscular

Indications

HIV infectious disease